Skip to main content

Table 1 Demographic characteristics of the treatment groups

From: Pain experience in children with juvenile idiopathic arthritis treated with anti-TNF agents compared to non-biologic standard treatment

  Standard treatment group (n = 50) Anti-TNF group (n = 41) Group differences p-values
Age (year): mean (S.D.) 11.8 (2.0) 13.8 (2.4) Z = −3.79 <0.001
Gender (male) 9 (18.0%) 12 (29.3%) χ2(1) = 1.04 0.31
JIA subtype:    χ2(6) = 13.0 0.04
Systemic arthritis 5 (10.0%) 9 (22.0%)   
Oligoarthritis persistent 11 (22.0%) 1 (2.4%)   
Oligoarthritis extended 9 (18.0%) 9 (22.0%)   
Polyarthritis (RF-negative) 22 (44.0%) 17 (41.5%)   
Polyarthritis (RF-positive) 0 (0.0%) 1 (2.4%)   
Psoriatic arthritis 1 (2.0%) 2 (4.9%)   
Enthesitis-related arthritis 0 (0.0%) 2 (4.9%)   
Data on subtype n.a. 2 (4.0%)    
Disease duration (year): mean (S.D.)a 5.2 (3.6) 8.0 (3.6) Z = −3.23 0.001
Current use of medication:     
NSAID use: 41 (82.0%) 17 (41.5%) χ2(1) = 14.31 <0.001
Use of other analgesics: 10 (20.0%) 15 (36.6%) χ2(1) = 2.33 0.13
Methotrexate use: 18 (36.0%) 17 (41.5%) χ2(1) = 0.10 0.75
Anti-TNF agents use:     
Etanercept   31 (75.6%)   
Adalimumbab   3 (7.3%)   
Infliximab   3 (7.3%)   
Treatment time with anti-TNF agents (year)   2.4 (1.8)   
  1. aDisease duration was defined as the time from the onset of the symptoms to the participation in the study.